Our mission

Expanding access to safe and effective cell-based therapies

Our mission is to expand access to safe and effective cell-based therapies for patients with pancreatic diseases, including chronic pancreatitis and type 1 diabetes. We combine deep clinical expertise with innovative cellular technologies to deliver high-quality islet cell therapies that prioritize patient safety and long-term outcomes.

Our expertise

Among the most experienced islet cell teams in the United States

Our islet cell specialists have participated in more than 200 clinical islet isolation procedures and are among the most experienced teams in the United States in total pancreatectomy with islet autotransplantation (TPIAT). This extensive expertise forms the foundation of IsleNova's commitment to excellence in islet cell processing.

200+
Clinical islet isolation procedures
Our specialists have participated in over 200 clinical islet isolation procedures — one of the highest volumes in the country.
TPIAT
Specialized in islet autotransplantation
Deep expertise in total pancreatectomy with islet autotransplantation for chronic pancreatitis patients.
cGTP
FDA-compliant processing standards
Committed to FDA current Good Tissue Practice standards for the highest levels of safety and quality in cell processing.
What drives us

Our core commitments

Everything we do is guided by a commitment to patient safety, clinical excellence, and translational innovation.

Patient safety first
Every protocol, every procedure, every decision is made with patient safety as the non-negotiable priority.
Clinical excellence
Our team brings unmatched procedural experience to every islet isolation — setting the standard for quality in cell processing.
Translational innovation
We are bridging the gap between clinical practice and next-generation regenerative medicine — moving science from bench to bedside.

Work with IsleNova

Whether you're a physician exploring a future partnership or an investor aligned with our mission, we'd like to connect.

For physicians →Investor overview →